Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
PRECISION BIOSCIENCES INC Chief Research Officer J. Jefferson Smith received a grant of 57,389 Restricted Stock Units. Each unit represents a contingent right to receive one share of common stock, so this award could convert into 57,389 shares if fully vested.
The RSU award vests in three substantially equal annual installments beginning on February 19, 2027, conditioned on Smith’s continued service with the company through each vesting date. Following this grant, Smith’s reported derivative holdings from this award total 57,389 RSUs, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
Scimeca Dario reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC reported that its General Counsel and Secretary, Dario Scimeca, received a grant of 107,604 restricted stock units. Each unit represents a contingent right to receive one share of the company’s common stock at no purchase price.
The award vests in three substantially equal annual installments beginning on February 18, 2027, conditioned on his continued service with the company through each vesting date. Following this grant, he holds 107,604 restricted stock units directly.
PRECISION BIOSCIENCES INC reported that Chief Financial Officer Kelly John Alexander received a grant of 193,688 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of common stock at no exercise price. The award vests in three substantially equal annual installments beginning on February 19, 2027, conditioned on his continued service with the company through each vesting date. Following this grant, he is reported as holding 193,688 RSUs directly.
Amoroso Michael reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC President and CEO Michael Amoroso reported a compensation-related equity grant. He received 573,888 Restricted Stock Units, each representing a contingent right to receive one share of the company’s common stock. The award vests in three substantially equal annual installments beginning on February 18, 2027, conditioned on his continued service with the company. Following this grant, his reported holding of these RSUs is 573,888 units.
Precision BioSciences reported new Phase 1 ELIMINATE-B data for its gene-editing therapy PBGENE-HBV in chronic hepatitis B. Liver biopsies showed direct elimination of cccDNA with a 1-log (10-fold) reduction in cccDNA-derived transcripts after dosing, and further edits in the small fraction remaining inactivated viral polymerase to stop replication.
Blood pgRNA, a marker that comes from cccDNA, was completely lost in 100% of treated patients with detectable pgRNA at baseline, and all evaluated patients showed substantial HBsAg declines, suggesting broad antiviral activity. Across 38 doses in 16 patients, no dose-limiting toxicities occurred; common effects were short-lived infusion reactions and reversible liver enzyme elevations. A mitigation protocol for hypotension and liver labs has been implemented, with no new Grade 3 events reported since.
Precision BioSciences, Inc. reported the results of its annual stockholder meeting and related corporate changes. Stockholders approved an amendment and restatement of the 2019 Incentive Award Plan, increasing the shares of common stock available for issuance by 3,800,000 shares.
They also approved an amendment to the Amended and Restated Certificate of Incorporation to provide for the exculpation of certain officers as permitted by Delaware law, which became effective upon filing on May 22, 2026. All six proposals on the ballot, including director elections, auditor ratification, say-on-pay, the incentive plan amendment, the charter amendment, and a potential adjournment, received sufficient votes for approval.
PRECISION BIOSCIENCES INC director Kevin Buehler reported the vesting and settlement of restricted stock units into common shares. On May 20, 2026, 21,000 RSUs converted into 21,000 shares of common stock at no cash exercise price. These RSUs were granted on June 3, 2025 and vested based on continued service. Following this equity award vesting, Buehler directly owns 49,137 shares of common stock and did not report any share sales in this filing.
PRECISION BIOSCIENCES INC director Stanley Frankel reported the vesting of equity awards, rather than an open-market trade. On May 20, 2026, 21,000 Restricted Stock Units (RSUs) converted into the same number of shares of common stock at an exercise price of $0.00 per share.
These RSUs were originally granted on June 3, 2025 and vested based on continued service and the timing of the company’s next annual stockholders’ meeting. Following this vesting event, Frankel directly holds 40,478 shares of Precision BioSciences common stock. The filing does not show any same-day sale of these shares, so this appears to be a routine compensation-related equity vesting and exercise.
PRECISION BIOSCIENCES INC director Melinda Brown acquired 21,000 shares of Common Stock through RSU vesting. On May 20, 2026, 21,000 Restricted Stock Units converted into the same number of common shares at a price of $0.00 per share, reflecting equity compensation rather than a market purchase.
Each RSU provided a contingent right to receive one share of common stock, based on an award granted on June 3, 2025. Following this vesting event, Brown directly holds 44,346 common shares. No shares were sold, gifted, or withheld for taxes in this filing.
PRECISION BIOSCIENCES INC director Shari Lisa Pire reported a compensation-related share acquisition. On May 20, 2026, 21,000 Restricted Stock Units vested and were settled into 21,000 shares of Common Stock. No sale was reported, and she now directly holds 35,028 Common Shares.
The RSUs were originally granted on June 3, 2025 and were scheduled to vest on the earlier of June 3, 2026 or the day before the next annual stockholder meeting, subject to her continued service. Each RSU represented the right to receive one share of Common Stock upon vesting.